RESUMEN
Natural killer (NK) cells are a potent weapon against tumor and viral infection. Finding active compounds with the capacity of enhancing NK cell effector functions will be effective to develop new anti-cancer drugs. In this study, we initially screened 287 commercially available active compounds by co-culturing with peripheral blood mononuclear cells (PBMCs). We found that five compounds, namely, Daphnetin, MK-8617, LW6, JIB-04, and IOX1, increased the IFN-γ+ NK cell ratio in the presence of IL-12. Further studies using purified human primary NK cells revealed that Daphnetin directly promoted NK cell IFN-γ production in the presence of IL-12 but not IL-15, while the other four compounds acted on NK cells indirectly. Daphnetin also improved the direct cytotoxicity of NK cells against tumor cells in the presence of IL-12. Through RNA-sequencing, we found that PI3K-Akt-mTOR signaling acted as a central pathway in Daphnetin-mediated NK cell activation in the presence of IL-12. This was further confirmed by the finding that both inhibitors of PI3K-Akt and its main downstream signaling mTOR, LY294002, and rapamycin, respectively, can reverse the increase of IFN-γ production and cytotoxicity in NK cells promoted by Daphnetin. Collectively, we identify a natural product, Daphnetin, with the capacity of promoting human NK cell activation via PI3K-Akt-mTOR signaling in the presence of IL-12. Our current study opens up a new potential application for Daphnetin as a complementary immunomodulator for cancer treatments.
Asunto(s)
Citotoxicidad Inmunológica/efectos de los fármacos , Interferón gamma/biosíntesis , Células Asesinas Naturales/efectos de los fármacos , Activación de Linfocitos/efectos de los fármacos , Umbeliferonas/farmacología , Acetanilidas/farmacología , Adamantano/análogos & derivados , Adamantano/farmacología , Adolescente , Adulto , Aminopiridinas/farmacología , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/farmacología , Femenino , Humanos , Hidrazonas/farmacología , Hidroxiquinolinas/farmacología , Interferón gamma/genética , Interleucina-12/fisiología , Células K562 , Células Asesinas Naturales/inmunología , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/inmunología , Masculino , Persona de Mediana Edad , Fosfatidilinositol 3-Quinasas/fisiología , Proteínas Proto-Oncogénicas c-akt/fisiología , Piridazinas/farmacología , Pirimidinas/farmacología , Transducción de Señal , Serina-Treonina Quinasas TOR/fisiología , Adulto JovenRESUMEN
Exogenous treatment of a neurotensin receptor 1 (NTR1) agonist exerted the neuroprotection in an obese and Alzheimer's model. However, the effects of NTR1 modulation on peripheral/hippocampal impairment and cognitive deficit following sustained HFD consumption are poorly understood. Forty rats received a normal diet (ND) or HFD for 16 weeks. At week 13, the ND group received a vehicle (n = 8). Thirty-two HFD-fed group were randomized into four subgroups (n = 8/subgroup) with a vehicle, 1 mg/kg of NTR1 agonist, 1 mg/kg of NTR antagonist, and combined treatment (NTR1 agonist-NTR antagonist) for 2 weeks, s.c. injection. Then, the cognitive tests and peripheral/hippocampal parameters were determined. Our findings demonstrated that NTR1 activator reversed obesity and attenuated metabolic impairment in pre-diabetic rats. It also alleviated hippocampal pathologies and synaptic dysplasticity, leading to deceleration or prevention of cognitive impairment progression. Therefore, NTR1 activation would be a possible novel therapy to decelerate or prevent progression of neuropathology and cognitive impairment in the pre-diabetes.
Asunto(s)
Adamantano/análogos & derivados , Disfunción Cognitiva/tratamiento farmacológico , Hipocampo/efectos de los fármacos , Imidazoles/uso terapéutico , Obesidad/tratamiento farmacológico , Oligopéptidos/uso terapéutico , Receptores de Neurotensina/agonistas , Adamantano/farmacología , Adamantano/uso terapéutico , Animales , Disfunción Cognitiva/etiología , Dieta Alta en Grasa , Evaluación Preclínica de Medicamentos , Quimioterapia Combinada , Hipocampo/metabolismo , Íleon/efectos de los fármacos , Íleon/metabolismo , Imidazoles/farmacología , Resistencia a la Insulina , Masculino , Plasticidad Neuronal/efectos de los fármacos , Obesidad/complicaciones , Oligopéptidos/farmacología , Estrés Oxidativo/efectos de los fármacos , Estado Prediabético/tratamiento farmacológico , Estado Prediabético/metabolismo , Distribución Aleatoria , Ratas Wistar , Receptores de Neurotensina/antagonistas & inhibidores , Receptores de Neurotensina/metabolismoRESUMEN
ETHNOPHARMACOLOGICAL RELEVANCE: Stevia rebaudiana Bertoni is a perennial herb that belongs to the Asteraceae family. It is a natural sweetener plant known as "Sweet Leaf", "Sweet Herbs" and "Honey Leaf", which is estimated to be 300 times more sweetening than sugar cane. Stevia has been used as a traditional treatment for diabetes in many countries for hundreds of years. Several animal studies referred to the antihyperglycemic activity of stevia. However, the combined use of stevia with saxagliptin has not been studied so far, so this study has been done. The aim of the present study was to evaluate the antihyperglycemic effect of stevia alone and in combination with saxagliptin. MATERIALS AND METHODS: Diabetes was induced in rats by i.p. injection of streptozotocin and nicotinamide. Animals were divided into five groups, each contains eight rats. Group I: included negative controland group II: included diabetic control that received saline. Group III: included diabetic rats that received 400 mg/kg/day stevia aqueous extract. Group IV: included diabetic rats that received saxagliptin 10 mg/kg/day. Group V: included diabetic rats that received stevia 400 mg/kg + saxagliptin 10 mg/kg. Food and water intake were measured daily while body weight was measured weekly. After 3 weeks animals were sacrificed and blood and tissue samples were collected. Fasting blood glucose (FBG), serum insulin, serum dipeptidylepeptidase-4 (DPP-4), TC, TGs, LDL, HDL, GSH and MDA were measured in treated and control rats by colorimetric and ELISA methods. RESULTS: Both stevia and saxagliptin significantly reduced food, water intake, body weight and FBG. Stevia with saxagliptin produced more significant decrease in FBG. While serum insulin increased significantly in stevia, saxagliptin treated groups and their combination. Serum DPP-4 decreased significantly in all treated groups, concerning lipid profile, stevia and saxagliptin notably lowered TC, TGs, and LDL and increased HDL. Both stevia and saxagliptin remarkably decreased MDA and increased GSH compared to diabetic rats. In addition, stevia significantly improved the antidiabetic effects of saxagliptin. CONCLUSION: Stevia has an antihyperglycemic effect and could enhance the antidiabetic activity of saxagliptin. DPP-4 attenuation, antihyperlipidemic and antioxidant activity as well as improvement of insulin sensitivity may be involved in the antidiabetic action of stevia.
Asunto(s)
Adamantano/análogos & derivados , Diabetes Mellitus Experimental/tratamiento farmacológico , Dipéptidos/farmacología , Hipoglucemiantes/farmacología , Extractos Vegetales/farmacología , Stevia/química , Adamantano/administración & dosificación , Adamantano/farmacología , Animales , Antioxidantes/aislamiento & purificación , Antioxidantes/farmacología , Glucemia/efectos de los fármacos , Diabetes Mellitus Experimental/fisiopatología , Dipéptidos/administración & dosificación , Interacciones de Hierba-Droga , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/aislamiento & purificación , Hipolipemiantes/aislamiento & purificación , Hipolipemiantes/farmacología , Resistencia a la Insulina , Masculino , Niacinamida , Extractos Vegetales/administración & dosificación , Ratas , Ratas Wistar , EstreptozocinaRESUMEN
Hypersubones D-H (1-5), five new polycyclic polyprenylated acylphloroglucinols (PPAPs) type metabolites with intriguing adamantane and homo-adamantane skeletons, were characterized from aerial parts of Hypericum subsessile. Compounds 1-2 were elucidated to share an adamantane core with 28,29-expoxide moiety, while 3-5 were homo-adamantane type PPAPs sharing a1,2-dioxepane ring system. Their structures were determined on the basis of comprehensive NMR and MS spectroscopic data.The anti-adipogenesis activities of these isolates were evaluated through employing 3T3-L1 cells as an in vitro system using oil red O staining, and compounds 1, 2 and 5 were able to significant inhibit the adipocyte differentiation, which implied that these compounds possessed anti-adipogenic activity.
Asunto(s)
Adamantano/farmacología , Adipocitos/efectos de los fármacos , Hypericum/química , Células 3T3-L1 , Adamantano/aislamiento & purificación , Animales , Diferenciación Celular/efectos de los fármacos , China , Ratones , Estructura Molecular , Fitoquímicos/aislamiento & purificación , Fitoquímicos/farmacología , Componentes Aéreos de las Plantas/químicaRESUMEN
Extracellular calcium is required for intracellular Ca2+ oscillations needed for egg activation, but the regulatory mechanism is still poorly understood. The present study was designed to demonstrate the function of calcium-sensing receptor (CASR), which could recognize extracellular calcium as first messenger, during porcine egg activation. CASR expression was markedly upregulated following egg activation. Functionally, the addition of CASR agonist NPS R-568 significantly enhanced pronuclear formation rate, while supplementation of CASR antagonist NPS2390 compromised egg activation. There was no change in NPS R-568 group compared with control group when the egg activation was performed without extracellular calcium addition. The addition of NPS2390 precluded the activation-dependent [Ca2+ ]i rise. When egg activation was conducted in intracellular Ca2+ chelator BAPTA-AM and NPS R-568 containing medium, CASR function was abolished. Meanwhile, CASR activation increased the level of the [Ca2+ ]i effector p-CAMKII, and the presence of KN-93, an inhibitor of CAMKII, significantly reduced the CASR-mediated increasement of pronuclear formation rate. Furthermore, the increase of CASR expression following activation was reversed by inhibiting CAMKII activity, supporting a positive feedback loop between CAMKII and CASR. Altogether, these findings provide a new pathway of egg activation about CASR, as the extracellular Ca2+ effector, promotes egg activation via its downstream effector and upstream regulator CAMKII.
Asunto(s)
Proteína Quinasa Tipo 2 Dependiente de Calcio Calmodulina/fisiología , Fertilización/fisiología , Receptores Sensibles al Calcio/fisiología , Porcinos/fisiología , Adamantano/análogos & derivados , Adamantano/farmacología , Animales , Bencilaminas/farmacología , Señalización del Calcio/efectos de los fármacos , Señalización del Calcio/fisiología , Proteína Quinasa Tipo 2 Dependiente de Calcio Calmodulina/metabolismo , Células Cultivadas , Ácido Egtácico/análogos & derivados , Ácido Egtácico/farmacología , Femenino , Fertilización/efectos de los fármacos , Masculino , Fenetilaminas/farmacología , Propilaminas/farmacología , Quinoxalinas/farmacología , Receptores Sensibles al Calcio/antagonistas & inhibidores , Transducción de Señal/efectos de los fármacos , Interacciones Espermatozoide-Óvulo/efectos de los fármacos , Sulfonamidas/farmacologíaRESUMEN
The aim of the study was to examine possible impacts of paroxetine and agomelatine on the levels of some components that constitute the seminal vesicle fluid. As a second purpose, it was also aimed to examine how possible negative effects induced by paroxetine on seminal vesicle fluid components were affected by kisspeptin and RF9 (an RFamide-related peptide antagonist, RFRP). Forty-two male rats, aged 21 days, divided into six groups; control, sham, paroxetine, agomelatine, paroxetine + kisspeptin and paroxetine + RF9. Paroxetine (3.6 mg/kg) and agomelatine (10 mg/kg) were administrated by oral gavage. Kisspeptin (1 nmol) and RF9 (20 nmol) were administered intracerebroventricular (i.c.v). The experiments were ended on post-natal 120 days; fructose, vitamin E, sodium, potassium and magnesium levels were measured in seminal vesicle fluid. Fructose, vitamin E, magnesium and potassium levels were significantly decreased in seminal vesicle fluid from the rats treated with paroxetine but did not show significant differences following agomelatine administration. The co-administration of kisspeptin or RF9 with paroxetine prevented the paroxetine-induced negative effects on seminal vesicle fluid components. These results suggest that reduction in sperm fertilising ability caused by changes in seminal vesicle fluid can be seen in long-term antidepressant use. RF-9 and kisspeptin might have positive effects on long-term antidepressant use-induced infertility.
Asunto(s)
Acetamidas/efectos adversos , Paroxetina/efectos adversos , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Semen/efectos de los fármacos , Adamantano/análogos & derivados , Adamantano/farmacología , Adamantano/uso terapéutico , Animales , Dipéptidos/farmacología , Dipéptidos/uso terapéutico , Evaluación Preclínica de Medicamentos , Kisspeptinas/farmacología , Kisspeptinas/uso terapéutico , Masculino , Distribución Aleatoria , Ratas , Ratas Sprague-DawleyRESUMEN
Hypogonadotropic hypogonadism (secondary hypogonadism), congenital or acquired, is a form of hypogonadism that is due to problems with either the hypothalamus or pituitary gland affecting gonadotropin levels. Pulsatile secretion of gonadotropin-releasing hormone (GnRH) by hypothalamus is a primer step to initiate the release of pituitary gonadotropins. Kisspeptin and gonadotropin-inhibitory hormone (GnIH) are accepted as two major players in the activation and inhibition of GnRH regarding the neuroendocrine functioning of the hypothalamic pituitary gonadal axis. Kisspeptin is known as the most potent activator of GnRH. Regarding the inhibition of GnRH, RF-amide-related peptide-3 (RFRP-3) is accepted as the mammalian orthologue of GnIH in avian species. RF9 (1-adamantane carbonyl-Arg-Phe-NH2) is an antagonist of RFRP-3/GnIH receptor (neuropeptide FF receptor 1 (NPFFR1; also termed as GPR147). In recent years, several studies have indicated that RF9 activates GnRH neurons and gonadotropins in a kisspeptin receptor (Kiss1r, formerly known as GPR54) dependent manner. These results suggest that RF9 may have a bimodal function as both an RFRP-3 antagonist and a kisspeptin agonist or it may be a kiss1r agonist rather than an RFRP-3/GnIH receptor antagonist. These interactions are possible because Kisspeptin and GnIH are members of the RF-amide family, and both possibilities are not far from explaining the potent gonadotropin stimulating effects of RF9. Therefore, we hypothesize that RF9 may be a new therapeutic option for the hypogonadotropic hypogonadism due to its potent GnRH stimulating effects. A constant or repeated administration of RF9 provides a sustained increase in plasma gonadotrophin levels. However, applications in the same way with GnRH analogues and kisspeptin may result in desensitization of the gonadotropic axis. The reasons reported above contribute to our hypothesis that RF9 may be a good option in the GnRH stimulating as a kisspeptin agonist. We suggest that further studies are needed to elucidate the potential effects of RF9 in the treatment of the hypogonadotropic hypogonadism.
Asunto(s)
Adamantano/análogos & derivados , Dipéptidos/farmacología , Hormona Liberadora de Gonadotropina/metabolismo , Gonadotropinas/metabolismo , Hipogonadismo/metabolismo , Hipotálamo/metabolismo , Adamantano/farmacología , Animales , Células CHO , Cricetinae , Cricetulus , Humanos , Hipogonadismo/terapia , Ratones , Modelos Biológicos , Modelos Teóricos , Neuropéptidos/metabolismo , Ratas , Receptores de Kisspeptina-1/metabolismo , Receptores de Neuropéptido/metabolismoRESUMEN
Acute inflammation induces sensitization of nociceptive neurons and triggers the accumulation of calcium permeable (CP) α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs) in the dorsal horn of the spinal cord. This coincides with behavioral signs of acute inflammatory pain, but whether CP-AMPARs contribute to chronic pain remains unclear. To evaluate this question, we first constructed current-voltage (IV) curves of C-fiber stimulus-evoked, AMPAR-mediated EPSCs in lamina II to test for inward rectification, a key characteristic of CP-AMPARs. We found that the intraplantar injection of complete Freund's adjuvant (CFA) induced an inward rectification at 3â¯d that persisted to 21â¯d after injury. Furthermore, the CP- AMPAR antagonist IEM-1460 (50⯵M) inhibited AMPAR-evoked Ca2+ transients 21d after injury but had no effect in uninflamed mice. We then used a model of long-lasting vulnerability for chronic pain that is determined by the balance between latent central sensitization (LCS) and mu opioid receptor constitutive activity (MORCA). When administered 21â¯d after the intraplantar injection of CFA, intrathecal administration of the MORCA inverse agonist naltrexone (NTX, 1⯵g, i.t.) reinstated mechanical hypersensitivity, and superfusion of spinal cord slices with NTX (10⯵M) increased the peak amplitude of AMPAR-evoked Ca2+ transients in lamina II neurons. The CP-AMPAR antagonist naspm (0-10â¯nmol, i.t.) inhibited these NTX-induced increases in mechanical hypersensitivity. NTX had no effect in uninflamed mice. Subsequent western blot analysis of the postsynaptic density membrane fraction from lumbar dorsal horn revealed that CFA increased GluA1 expression at 2â¯d and GluA4 expression at both 2 and 21â¯d post-injury, indicating that not just the GluA1 subunit, but also the GluA4 subunit, contributes to the expression of CP-AMPARs and synaptic strength during hyperalgesia. GluA2 expression increased at 21â¯d, an unexpected result that requires further study. We conclude that after tissue injury, dorsal horn AMPARs retain a Ca2+ permeability that underlies LCS. Because of their effectiveness in reducing naltrexone-induced reinstatement of hyperalgesia and potentiation of AMPAR-evoked Ca2+ signals, CP-AMPAR inhibitors are a promising class of agents for the treatment of chronic inflammatory pain.
Asunto(s)
Calcio/metabolismo , Dolor Crónico/fisiopatología , Receptores AMPA/metabolismo , Receptores Opioides/metabolismo , Médula Espinal/metabolismo , Médula Espinal/fisiopatología , Adamantano/análogos & derivados , Adamantano/farmacología , Animales , Dolor Crónico/inducido químicamente , Potenciales Postsinápticos Excitadores/efectos de los fármacos , Adyuvante de Freund , Masculino , Ratones , Ratones Endogámicos C57BL , Naltrexona/farmacología , Antagonistas de Narcóticos/farmacología , Fibras Nerviosas Amielínicas , Nocicepción , Células del Asta Posterior/efectos de los fármacos , Receptores AMPA/antagonistas & inhibidores , Receptores de Glutamato/metabolismo , Sinapsis/efectos de los fármacosRESUMEN
Hookeriones I-Q (1-9), nine new homo-adamantane type polycyclic polyprenylated acylphloroglucinols (PPAPs), were isolated from Hypericum hookerianum, along with twenty known analogues. These structures were determined on the basis of comprehensive NMR and MS spectroscopic data. Comprehensive analysis of the NMR data revealed the correlations between the configuration of H-18 and H-28 and the chemical shifts of related signals. The cytotoxicity and anti-allergic activities of the new isolates were evaluated, and several ones exhibited moderate cytotoxicity against ECA-109 cell lines.
Asunto(s)
Adamantano/farmacología , Hypericum/química , Floroglucinol/farmacología , Adamantano/aislamiento & purificación , Animales , Línea Celular , Línea Celular Tumoral , China , Humanos , Estructura Molecular , Floroglucinol/aislamiento & purificación , Fitoquímicos/aislamiento & purificación , Fitoquímicos/farmacología , Componentes Aéreos de las Plantas/química , RatasRESUMEN
This study compared dipeptidyl peptidase-4 (DPP-4) inhibitory activity of citrus bioflavonoid nutraceuticals compared with three gliptins. Citrus bioflavonoid standards and three commercially available citrus bioflavonoid supplements (Thompson's Super Bioflavonoid Complex®(SB), Ethical Nutrients Bioflavonoids Plus Vitamin C®(EN), and Country Life Citrus Bioflavonoids and Rutin®(CB)) were considered in this study. Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) analysis was undertaken to identify and quantitate the citrus bioflavonoids present in each supplement. The DPP-4 inhibitory activity was determined by fluorometric assay. All of the tested individual citrus flavonoids demonstrated DPP-4 inhibitory activity, with IC50 values ranging from 485⯵M (rutin) to 5700⯵M (hesperitin and eriodictyol). Similarly, the flavonoid supplements had IC50 values of 16.9â¯mg/mL (EN), 3.44â¯mg/mL (SB) and 2.72â¯mg/mL (CB). These values compare with gliptin IC50 values of 0.684⯵M (sitagliptin), 0.707⯵M (saxagliptin) and 2.286⯵M (vildagliptin). The supplement flavonoid content varied from 11.98% (CB) to 5.26% (EN) and 14.51% (SB) of tablet mass, corresponding to daily flavonoid doses of around 300, 150 and 400â¯mg, respectively, with CB and SB containing rutin at levels of 7.0% and 7.5% of tablet mass, respectively. While our data demonstrated that citrus bioflavonoid based supplements do possess DPP-4 inhibitory activity, they are several orders of magnitude less potent than gliptins. Further studies using higher concentrations of citrus bioflavonoids, as well as investigations into antioxidant properties which may add additional benefit are warranted.
Asunto(s)
Citrus/química , Inhibidores de la Dipeptidil-Peptidasa IV/química , Inhibidores de la Dipeptidil-Peptidasa IV/farmacología , Flavonoides/química , Flavonoides/farmacología , Hipoglucemiantes/química , Hipoglucemiantes/farmacología , Adamantano/análogos & derivados , Adamantano/química , Adamantano/farmacología , Simulación por Computador , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Dipéptidos/química , Dipéptidos/farmacología , Dipeptidil Peptidasa 4/química , Inhibidores de la Dipeptidil-Peptidasa IV/administración & dosificación , Flavonoides/administración & dosificación , Humanos , Hipoglucemiantes/administración & dosificación , Técnicas In Vitro , Simulación del Acoplamiento Molecular , Nitrilos/química , Nitrilos/farmacología , Pirrolidinas/química , Pirrolidinas/farmacología , Fosfato de Sitagliptina/química , Fosfato de Sitagliptina/farmacología , Espectrometría de Fluorescencia , Espectrometría de Masas en Tándem , VildagliptinaRESUMEN
In this study, a reduction-sensitive supramolecular polymeric drug delivery system was developed for combinational photothermal-chemotherapy of cancer. The multifunctional system was self-assembled by specific host-guest interactions between hydrophilic ß-cyclodextrin functionalized hyaluronic acid and adamantane linked camptothecin/dye conjugate, where a near-infrared (NIR) absorbing dye IR825 was loaded. The hydrophilic hyaluronic acid shell endows the assembly with excellent colloidal stability and biocompatibility. The embedded disulfide bond in the camptothecin/dye conjugate was cleaved under reducing environment, leading to the release of the conjugated drug and the recovery of fluorescence emission. Meanwhile, the dye IR825 could efficiently transfer the absorbed light into local heat, making the nanoplatform an effective system for photothermal therapy. As evident by confocal microscopy images, the nanoplatform was quickly internalized by HeLa, MCF-7, and U14 cancer cells and released drug molecules inside the cells. In vitro cell viability assays confirmed that the cancer cells were efficiently killed by the treatment of the nanoplatform under NIR light irradiation. Significant tumor regression was also observed in the tumor-bearing mice upon the administration of the nanoplatform through combinational photothermal-chemotherapy therapy. Hence, this nanoplatform presented a great potential in site-specific combined photothermal-chemotherapy of tumor.
Asunto(s)
Antineoplásicos/química , Benzoatos/química , Colorantes Fluorescentes/química , Indoles/química , Nanopartículas/química , Polímeros/química , Profármacos/química , Adamantano/farmacología , Animales , Antineoplásicos/uso terapéutico , Camptotecina/química , Camptotecina/farmacología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Terapia Combinada , Portadores de Fármacos , Femenino , Humanos , Ácido Hialurónico/química , Interacciones Hidrofóbicas e Hidrofílicas , Rayos Infrarrojos , Ratones , Trasplante de Neoplasias , Oxidación-Reducción , Fototerapia/métodos , Profármacos/farmacologíaRESUMEN
It has been demonstrated that extracellular calcium is necessary in fertilisation and embryo development but the mechanism is still not well understood. The present study mainly focussed on the extracellular calcium effector called the calcium-sensing receptor (CASR) and examined its expression in porcine gametes and embryos and its function during fertilisation and early embryo development. By using reverse transcription polymerase chain reaction, CASR was found to be expressed in porcine oocytes, spermatozoa and embryos at different developmental stages. Functionally, medium supplementation with a CASR agonist or an antagonist during in vitro fertilisation (IVF) and in vitro culture (IVC) was tested. During fertilisation, the presence of a CASR agonist increased sperm penetration rate and decreased polyspermy rate leading to an increased normal fertilisation rate. During embryo development, for the IVF embryos, agonist treatment during IVC significantly increased cleavage rate and blastocyst formation rate compared with the control group. Furthermore, parthenogenetically activated embryos showed similar results with lower cleavage and blastocyst formation rates in the antagonist group than in the other groups. It was concluded that CASR, as the effector of extracellular calcium, modulates porcine fertilisation and early embryo development.
Asunto(s)
Blastocisto/metabolismo , Señalización del Calcio , Fase de Segmentación del Huevo/metabolismo , Fertilización In Vitro , Oocitos/metabolismo , Receptores Sensibles al Calcio/metabolismo , Espermatozoides/metabolismo , Adamantano/análogos & derivados , Adamantano/farmacología , Animales , Blastocisto/efectos de los fármacos , Calcimiméticos/farmacología , Señalización del Calcio/efectos de los fármacos , Fase de Segmentación del Huevo/efectos de los fármacos , Técnicas de Cultivo de Embriones , Regulación del Desarrollo de la Expresión Génica , Masculino , Oocitos/efectos de los fármacos , Fenetilaminas/farmacología , Propilaminas/farmacología , Quinoxalinas/farmacología , Receptores Sensibles al Calcio/efectos de los fármacos , Receptores Sensibles al Calcio/genética , Espermatozoides/efectos de los fármacos , Sus scrofaRESUMEN
Adamantanyl benzamide 1 was identified as a potent P2X7R antagonist but failed to progress further due to poor metabolic stability. We describe the synthesis and SAR of a series of bioisosteres of benzamide 1 to explore improvements in the pharmacological properties of this lead. Initial efforts investigated a series of heteroaromatic bioisosteres, which demonstrated improved physicochemical properties but reduced P2X7R antagonism. Installation of bioisosteric fluorine on the adamantane bridgeheads was well tolerated and led to a series of bioisosteres with improved physicochemical properties and metabolic stability. Trifluorinated benzamide 34 demonstrated optimal physicochemical parameters, superior metabolic stability (ten times longer than lead benzamide 1), and an improved physicokinetic profile and proved effective in the presence of several known P2X7R polymorphisms.
Asunto(s)
Adamantano/análogos & derivados , Benzamidas/farmacología , Antagonistas del Receptor Purinérgico P2X/farmacología , Receptores Purinérgicos P2X7/efectos de los fármacos , Adamantano/farmacología , Animales , Benzamidas/síntesis química , Benzamidas/química , Benzamidas/farmacocinética , Biotransformación , Evaluación Preclínica de Medicamentos , Estabilidad de Medicamentos , Humanos , Microsomas Hepáticos/metabolismo , Estructura Molecular , Oxidación-Reducción , Polimorfismo de Nucleótido Simple , Antagonistas del Receptor Purinérgico P2X/síntesis química , Antagonistas del Receptor Purinérgico P2X/química , Antagonistas del Receptor Purinérgico P2X/farmacocinética , Ratas , Receptores Purinérgicos P2X7/genética , Relación Estructura-ActividadRESUMEN
The Janus kinase (JAK) family of tyrosine kinases is associated with various cytokine receptors. JAK1 and JAK3 play particularly important roles in the immune response, and their inhibition is expected to provide targeted immune modulation. Several oral JAK inhibitors have recently been developed for treating autoimmune diseases, including rheumatoid arthritis (RA). Here, we investigated the pharmacological effects of peficitinib (formerly known as ASP015K), a novel, chemically synthesized JAK inhibitor. We found that peficitinib inhibited JAK1 and JAK3 with 50% inhibitory concentrations of 3.9 and 0.7 nM, respectively. Peficitinib also inhibited IL-2-dependent T cell proliferation in vitro and STAT5 phosphorylation in vitro and ex vivo. Furthermore, peficitinib dose-dependently suppressed bone destruction and paw swelling in an adjuvant-induced arthritis model in rats via prophylactic or therapeutic oral dosing regimens. Peficitinib also showed efficacy in the model by continuous intraperitoneal infusion. Area under the concentration versus time curve (AUC) at 50% inhibition of paw swelling via intraperitoneal infusion was similar to exposure levels of AUC at 50% inhibition via oral administration, implying that AUC might be important for determining the therapeutic efficacy of peficitinib. These data suggest that peficitinib has therapeutic potential for the oral treatment of RA.
Asunto(s)
Adamantano/análogos & derivados , Artritis Experimental/tratamiento farmacológico , Janus Quinasa 1/antagonistas & inhibidores , Janus Quinasa 3/antagonistas & inhibidores , Niacinamida/análogos & derivados , Adamantano/administración & dosificación , Adamantano/farmacología , Adamantano/uso terapéutico , Adyuvantes Inmunológicos/efectos adversos , Administración Oral , Animales , Artritis Experimental/inducido químicamente , Proliferación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Infusiones Parenterales , Masculino , Niacinamida/administración & dosificación , Niacinamida/farmacología , Niacinamida/uso terapéutico , Fosforilación/efectos de los fármacos , Ratas , Factor de Transcripción STAT5/sangre , Factor de Transcripción STAT5/metabolismo , Linfocitos T/fisiologíaAsunto(s)
Adamantano/análogos & derivados , Benzamidas/farmacología , Melanocitos/efectos de los fármacos , MicroARNs/metabolismo , Preparaciones para Aclaramiento de la Piel/farmacología , Adamantano/farmacología , Evaluación Preclínica de Medicamentos , Humanos , Queratinocitos/efectos de los fármacos , Queratinocitos/metabolismo , Metaloproteinasas de la Matriz/metabolismo , Melaninas/antagonistas & inhibidores , Melaninas/biosíntesis , Melanocitos/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Envejecimiento de la Piel/efectos de los fármacosRESUMEN
We report that the tuberculosis drug SQ109 [N-adamantan-2-yl-N'-((E)-3,7-dimethyl-octa-2,6-dienyl)-ethane-1,2-diamine] has potent activity against the intracellular amastigote form of Leishmania mexicana (50% inhibitory concentration [IC50], â¼11 nM), with a good selectivity index (>500). It is also active against promastigotes (IC50, â¼500 nM) and acts as a protonophore uncoupler, in addition to disrupting Ca(2+) homeostasis by releasing organelle Ca(2+) into the cytoplasm, and as such, it is an interesting new leishmaniasis drug hit candidate.
Asunto(s)
Adamantano/análogos & derivados , Antiprotozoarios/farmacología , Etilenodiaminas/farmacología , Leishmania mexicana/efectos de los fármacos , Adamantano/farmacología , Animales , Antituberculosos , Calcio/metabolismo , Línea Celular , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Concentración 50 Inhibidora , Leishmania mexicana/metabolismo , Macrófagos/efectos de los fármacos , Macrófagos/parasitología , RatonesRESUMEN
In order to investigate the in vivo dopamine (DA) stimulant properties of selected 3rd generation Spice/K2 cannabinoids, BB-22, 5F-PB-22, 5F-AKB-48 and STS-135, their in vitro affinity and agonist potency at native rat and mice CB1 receptors was studied. The compounds bind with high affinity to CB1 receptors in rat cerebral cortex homogenates and stimulate CB1-induced [(35)S]GTPγS binding with high potency and efficacy. BB-22 and 5F-PB-22 showed the lowest Ki of binding to CB1 receptors (0.11 and 0.13 nM), i.e., 30 and 26 times lower respectively than that of JWH-018 (3.38 nM), and a potency (EC50, 2.9 and 3.7 nM, respectively) and efficacy (Emax, 217% and 203%, respectively) as CB1 agonists higher than JWH-018 (EC50, 20.2 nM; Emax, 163%). 5F-AKB-48 and STS-135 had higher Ki for CB1 binding, higher EC50 and lower Emax as CB1 agonists than BB-22 and 5F-PB-22 but still comparatively more favourable than JWH-018. The agonist properties of all the compounds were abolished or drastically reduced by the CB1 antagonist/inverse agonist AM251 (0.1 µM). No activation of G-protein was observed in CB1-KO mice. BB-22 (0.003-0.01 mg/kg i.v.) increased dialysate DA in the accumbens shell but not in the core or in the medial prefrontal cortex, with a bell shaped dose-response curve and an effect at 0.01 mg/kg and a biphasic time-course. Systemic AM251 (1.0 mg/kg i.p.) completely prevented the stimulant effect of BB-22 on dialysate DA in the NAc shell. All the other compounds increased dialysate DA in the NAc shell at doses consistent with their in vitro affinity for CB1 receptors (5F-PB-22, 0.01 mg/kg; 5F-AKB-48, 0.1 mg/kg; STS-135, 0.15 mg/kg i.v.). 3rd generation cannabinoids can be even more potent and super-high CB1 receptor agonists compared to JWH-018. Future research will try to establish if these properties can explain the high toxicity and lethality associated with these compounds.
Asunto(s)
Adamantano/análogos & derivados , Agonistas de Receptores de Cannabinoides/farmacología , Dopaminérgicos/farmacología , Indazoles/farmacología , Indoles/farmacología , Quinolinas/farmacología , Adamantano/farmacología , Animales , Antagonistas de Receptores de Cannabinoides/farmacología , Estimulantes del Sistema Nervioso Central/farmacología , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Masculino , Ratones Endogámicos C57BL , Ratones Noqueados , Estructura Molecular , Naftalenos/farmacología , Núcleo Accumbens/efectos de los fármacos , Núcleo Accumbens/metabolismo , Piperidinas/farmacología , Corteza Prefrontal/efectos de los fármacos , Corteza Prefrontal/metabolismo , Pirazoles/farmacología , Ratas Sprague-Dawley , Receptor Cannabinoide CB1/agonistas , Receptor Cannabinoide CB1/antagonistas & inhibidores , Receptor Cannabinoide CB1/genética , Receptor Cannabinoide CB1/metabolismoRESUMEN
Ezrin is a member of the ERM (ezrin, radixin, moesin) family of proteins and functions as a linker between the plasma membrane and the actin cytoskeleton. Ezrin is a key driver of tumor progression and metastatic spread of osteosarcoma. We discovered a quinoline-based small molecule, NSC305787, that directly binds to ezrin and inhibits its functions in promoting invasive phenotype. NSC305787 possesses a very close structural similarity to commonly used quinoline-containing antimalarial drugs. On the basis of this similarity and of recent findings that ezrin has a likely role in the pathogenesis of malaria infection, we screened antimalarial compounds in an attempt to identify novel ezrin inhibitors with better efficacy and drug properties. Screening of Medicines for Malaria Venture (MMV) Malaria Box compounds for their ability to bind to recombinant ezrin protein yielded 12 primary hits with high selective binding activity. The specificity of the hits on ezrin function was confirmed by inhibition of the ezrin-mediated cell motility of osteosarcoma cells. Compounds were further tested for phenocopying the morphologic defects associated with ezrin suppression in zebrafish embryos as well as for inhibiting the lung metastasis of high ezrin-expressing osteosarcoma cells. The compound MMV667492 exhibited potent anti-ezrin activity in all biologic assays and had better physicochemical properties for drug-likeness than NSC305787. The drug-like compounds MMV020549 and MMV666069 also showed promising activities in functional assays. Thus, our study suggests further evaluation of antimalarial compounds as a novel class of antimetastatic agents for the treatment of metastatic osteosarcoma.
Asunto(s)
Adamantano/análogos & derivados , Antineoplásicos/farmacología , Proteínas del Citoesqueleto/antagonistas & inhibidores , Osteosarcoma/tratamiento farmacológico , Quinolinas/farmacología , Adamantano/farmacología , Animales , Antimaláricos/farmacología , Línea Celular Tumoral , Movimiento Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Proteínas del Citoesqueleto/metabolismo , Evaluación Preclínica de Medicamentos/métodos , Embrión no Mamífero/efectos de los fármacos , Embrión no Mamífero/embriología , Embrión no Mamífero/metabolismo , Immunoblotting , Neoplasias Pulmonares/prevención & control , Neoplasias Pulmonares/secundario , Ratones Endogámicos BALB C , Osteosarcoma/metabolismo , Osteosarcoma/patología , Bibliotecas de Moléculas Pequeñas/farmacología , Resonancia por Plasmón de Superficie , Pez Cebra/embriología , Pez Cebra/metabolismoRESUMEN
Synthetic cannabinoid (SC) designer drugs featuring bioisosteric fluorine substitution are identified by forensic chemists and toxicologists with increasing frequency. Although terminal fluorination of N-pentyl indole SCs is sometimes known to improve cannabinoid type 1 (CB1) receptor binding affinity, little is known of the effects of fluorination on functional activity of SCs. This study explores the in vitro functional activities of SC designer drugs JWH-018, UR-144, PB-22, and APICA, and their respective terminally fluorinated analogues AM-2201, XLR-11, 5F-PB-22, and STS-135 at human CB1 and CB2 receptors using a FLIPR membrane potential assay. All compounds demonstrated agonist activity at CB1 (EC50 = 2.8-1959 nM) and CB2 (EC50 = 6.5-206 nM) receptors, with the fluorinated analogues generally showing increased CB1 receptor potency (â¼2-5 times). Additionally, the cannabimimetic activities and relative potencies of JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135 in vivo were evaluated in rats using biotelemetry. All SCs dose-dependently induced hypothermia and reduced heart rate at doses of 0.3-10 mg/kg. There was no consistent trend for increased potency of fluorinated SCs over the corresponding des-fluoro SCs in vivo. Based on magnitude and duration of hypothermia, the SCs were ranked for potency (PB-22 > 5F-PB-22 = JWH-018 > AM-2201 > APICA = STS-135 = XLR-11 > UR-144).
Asunto(s)
Cannabinoides/química , Cannabinoides/farmacología , Drogas de Diseño/química , Drogas de Diseño/farmacología , Adamantano/análogos & derivados , Adamantano/química , Adamantano/farmacología , Animales , Línea Celular Tumoral , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Hipotermia/inducido químicamente , Indoles/química , Indoles/farmacología , Masculino , Ratones , Estructura Molecular , Naftalenos/química , Naftalenos/farmacología , Quinolinas/química , Quinolinas/farmacología , Ratas Wistar , Receptor Cannabinoide CB1/genética , Receptor Cannabinoide CB1/metabolismo , Receptor Cannabinoide CB2/genética , Receptor Cannabinoide CB2/metabolismo , TelemetríaRESUMEN
The emergence of glucagon-like peptide-1 as a crucial contender in modifying neurodegenerative diseases in the preclinical studies has instigated interest in investigating the antiparkinsonian effect of dipeptidyl peptidase (DPP)-4 inhibition. Notably, saxagliptin (SAX), the DPP-4 inhibitor, recently showed efficacy in ameliorating streptozotocin-induced Alzheimer's disease; however, its effect on Parkinson's disease (PD) has not yet been elucidated. In a rat rotenone (ROT) model, SAX prominently improved motor performance as well as muscle coordination and corrected akinesia. Moreover, SAX preserved substantia nigra pars compacta tyrosine hydroxylase (TH) immunoreactivity while halting the reduction in the striatal TH, dopamine (DA) and complex I. Meanwhile, SAX prevented the ROT-induced increment of striatal DPP-4 and the decline in cAMP, ATP/ADP and brain-derived neurotropic factor levels. Improvement in striatal energy level was associated with partial hindrance of ROT-induced body weight reduction. In addition, through its anti-inflammatory potential, SAX decreased the ROT-induced nuclear factor-κΒ, inducible nitric oxide synthase, tumor necrosis factor-α, intracellular adhesion molecule-1 and myeloperoxidase. The antiapoptotic marker B-cell lymphoma-2 was enhanced by SAX, versus reduction in caspase-3 and its intrinsic apoptotic activator cytochrome C. Furthermore, SAX amended alterations induced by ROT in the thiobarbituric acid reactive substances and the transcriptional factor Nrf-2 level. In conclusion, SAX can be introduced as a novel approach for the management of PD based on the remarkable improvement in motor functions denoting antiparkinsonian efficacy via antioxidant, anti-inflammatory, antiapoptotic, neuroprotective and neurorestorative mechanisms. These effects were linked to DPP-4 inhibition, reduced neurodegeneration and enhanced DA synthesis.